Prosecution Insights
Last updated: November 04, 2026

K-Gen Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

K-Gen Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being handled by a distinct examiner and is located in a distinct art unit. The current prosecution profile for this entity is focused on this one active matter, representing the full extent of its pending office actions. This concentration indicates that the company's current patenting efforts are focused on a single innovation, with the entire prosecution process currently funneled through one specific examination channel at the USPTO.

The busiest examiner for this portfolio is PATEL, SAGAR S, who is responsible for 1 pending office action. This examiner manages the entirety of the active prosecution currently active for the portfolio. With only a single distinct art unit involved, the prosecution is currently centralized within a single pharmaceutical examination group. The fact that a single distinct examiner is reviewing the 1 pending office action means that the outcome of this matter is dependent on the specific technical interpretations and procedural requirements of this individual.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PATEL, SAGAR S 1 75.6% +35.2%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18283787 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PATEL, SAGAR S —

Top Art Units

Art UnitApps
1626 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18283787 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PATEL, SAGAR S 1626 §102§112DP Non-Final OA — Pending Sep 23, 2023

Managing K-Gen Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does K-Gen Therapeutics Inc. have?

K-Gen Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most K-Gen Therapeutics Inc. applications?

Sagar S Patel has the most, with 1 of K-Gen Therapeutics Inc.'s pending office actions.

What technology area are K-Gen Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month